A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Running, not enrolling · Phase 1

Conditions studied: Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis

In brief

This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.

Key facts

Study ID

NCT06544330

Run by

Synthekine

People needed

48

Starts

2025-04-29

Expected to finish

2041-04-01

Last updated by the study team

2026-07-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• HonorHealth Research Institute — Scottsdale, Arizona, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Feinstein Institutes for Medical Research — Manhasset, New York, United States
• Columbia University Irving Medical Center — New York, New York, United States
• The Cleveland Clinic Foundation — Cleveland, Ohio, United States
• Ohio State University Wexner Medical Center — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.